Is tirzepatide better than Ozempic?

For weight loss, the head-to-head SURMOUNT-5 trial showed tirzepatide produced more loss, about 20% versus 14% for semaglutide at full obesity doses. For diabetes, SURPASS-2 also favored tirzepatide. "Better" still depends on the person, since cost, tolerance, insurance, and goals vary, but on the metabolic numbers alone tirzepatide is the more potent drug.

What is the difference between Zepbound and Mounjaro?

They are the same medicine, tirzepatide, sold under two names. Mounjaro is the version approved for type 2 diabetes; Zepbound is approved for weight management and, more recently, for obstructive sleep apnea in adults with obesity. Same molecule, different labeled uses.

How much weight will I lose on tirzepatide?

In the main trial, adults without diabetes lost about 21% of their body weight on average at the top dose over about 17 months, with people who stayed fully on the drug averaging a bit more. Results vary widely by person, dose reached, and how well nutrition and training support the medication. It is the largest average weight loss of any current drug.

Does tirzepatide cause muscle loss?

Some, yes. As with any large weight loss, part of what you lose is muscle. In tirzepatide studies the ratio was roughly 3 parts fat to 1 part muscle, so most of the loss is fat, but the muscle portion is enough that adequate protein and regular resistance training should start on day one to protect strength and metabolism.

Is tirzepatide safe for the heart?

The evidence points to yes on safety. In a large trial against another proven heart-protective drug, tirzepatide was non-inferior for cardiovascular events and reduced overall death, and in a separate trial it helped people with heart failure and obesity. What it has not yet shown, unlike semaglutide, is a placebo-controlled reduction in heart attacks and strokes; that trial is still running.

Is tirzepatide better than Ozempic?

For weight loss, the head-to-head SURMOUNT-5 trial showed tirzepatide produced more loss, about 20% versus 14% for semaglutide at full obesity doses. For diabetes, SURPASS-2 also favored tirzepatide. "Better" still depends on the person, since cost, tolerance, insurance, and goals vary, but on the metabolic numbers alone tirzepatide is the more potent drug.

What is the difference between Zepbound and Mounjaro?

They are the same medicine, tirzepatide, sold under two names. Mounjaro is the version approved for type 2 diabetes; Zepbound is approved for weight management and, more recently, for obstructive sleep apnea in adults with obesity. Same molecule, different labeled uses.

How much weight will I lose on tirzepatide?

In the main trial, adults without diabetes lost about 21% of their body weight on average at the top dose over about 17 months, with people who stayed fully on the drug averaging a bit more. Results vary widely by person, dose reached, and how well nutrition and training support the medication. It is the largest average weight loss of any current drug.

Does tirzepatide cause muscle loss?

Some, yes. As with any large weight loss, part of what you lose is muscle. In tirzepatide studies the ratio was roughly 3 parts fat to 1 part muscle, so most of the loss is fat, but the muscle portion is enough that adequate protein and regular resistance training should start on day one to protect strength and metabolism.

Is tirzepatide safe for the heart?

The evidence points to yes on safety. In a large trial against another proven heart-protective drug, tirzepatide was non-inferior for cardiovascular events and reduced overall death, and in a separate trial it helped people with heart failure and obesity. What it has not yet shown, unlike semaglutide, is a placebo-controlled reduction in heart attacks and strokes; that trial is still running.

Tirzepatide (Zepbound, Mounjaro): The Dual Incretin Drug | Philadelphia

TL;DR30-second take

Tirzepatide, sold as Zepbound for weight and Mounjaro for diabetes, is a dual GIP and GLP-1 receptor drug, a step beyond semaglutide, which targets GLP-1 alone. In trials it produced greater weight loss than semaglutide (about 20% versus 14% in a head-to-head study) and strong blood-sugar control. It also helped a difficult form of heart failure and reduced sleep apnea. Its cardiovascular evidence is promising but not yet the placebo-controlled heart-attack-and-stroke proof that semaglutide has. The main side effects are digestive, and it carries a thyroid-tumor boxed warning based on rodent data.

TL;DR: Tirzepatide, sold as Zepbound for weight and Mounjaro for type 2 diabetes, is a dual agonist that activates two gut-hormone receptors, GIP and GLP-1, where semaglutide (Ozempic, Wegovy) activates only GLP-1. That extra target translates into more weight loss: in a head-to-head trial it produced about 20% loss versus about 14% for semaglutide at its full obesity dose. It also lowers blood sugar powerfully, improves a hard-to-treat form of heart failure, and reduces obstructive sleep apnea. Its cardiovascular evidence is encouraging but does not yet include the placebo-controlled reduction in heart attacks and strokes that semaglutide showed in the SELECT trial. Side effects are mostly digestive, and it carries a boxed warning for thyroid tumors based on rodent data. Most weight lost is fat, though a meaningful share is muscle, which is why protein and resistance training matter.

What is tirzepatide, and how is it different from Ozempic?

Tirzepatide is a once-weekly injection that mimics two of the gut hormones your body releases after a meal: GLP-1 and GIP. Semaglutide, the drug behind Ozempic and Wegovy, mimics only GLP-1. Because tirzepatide engages both receptors, it is often called a dual agonist, or a twincretin. The two hormones work along overlapping paths to slow stomach emptying, quiet appetite, and improve how the pancreas handles blood sugar. Adding GIP appears to amplify these effects and may ease some of the nausea that comes with GLP-1 alone, though that is still being studied.

The practical headline is potency. In the studies that put the two drugs side by side, tirzepatide has produced more weight loss and, in diabetes, greater blood-sugar reduction. That does not make it the right choice for everyone, since cost, tolerance, and goals differ, but it is the more powerful of the two on the metabolic measures.

How much weight do people lose on tirzepatide?

In SURMOUNT-1, the main obesity trial, adults with obesity and without diabetes lost about 20.9% of their body weight at the highest dose over 72 weeks, compared with about 3% on placebo.¹ That figure is the treatment-regimen average, which counts everyone assigned to the drug including those who stopped; people who stayed on the full dose as directed averaged closer to 22.5%. Either way, this is the largest weight loss seen from a medication short of surgery.

The head-to-head question was answered in SURMOUNT-5, which compared tirzepatide against semaglutide at each drug's full obesity dose. Tirzepatide produced about 20.2% weight loss versus about 13.7% for semaglutide over 72 weeks.² Because both drugs were dosed to their obesity maximum, this was a fair comparison, and tirzepatide came out ahead, with fewer people stopping for digestive side effects.

One caution belongs alongside those numbers. A large share of any rapid weight loss is fat, but some is muscle. In the body-composition substudy, fat fell by about a third while lean mass fell by about a tenth, roughly a 3-to-1 ratio of fat to muscle. Most of the loss is fat, which is good, but the muscle loss matters enough that protein intake and resistance training should be part of the plan from day one. Muscle loss on GLP-1 drugs covers this in depth.

What does it do for blood sugar and diabetes?

As Mounjaro, tirzepatide is a diabetes drug, and a strong one. In SURPASS-2, it was compared with semaglutide 1mg, the diabetes dose available at the time, in people with type 2 diabetes on metformin. Tirzepatide lowered A1c more and produced more weight loss across its doses.³ It helps to read that result carefully: the comparison was against semaglutide's 1mg diabetes dose, so it does not settle the obesity-dose question, which SURMOUNT-5 later addressed. Both results favor tirzepatide, but they are different comparisons.

For a person choosing between agents, Ozempic versus Metformin walks through where each metabolic drug fits, and tirzepatide sits at the high-potency end of that same spectrum.

Does tirzepatide protect the heart?

This is where careful framing matters most, because it is easy to overstate. Tirzepatide has good cardiovascular data, but it is a different and thinner body of evidence than semaglutide's.

The strongest heart result is SUMMIT, a trial in people who had both obesity and heart failure with a preserved ejection fraction, a stubborn type that has resisted most treatments. Tirzepatide reduced a combined measure of cardiovascular death or worsening heart failure, and it improved symptoms and quality of life.⁴ The benefit was driven mainly by fewer heart-failure events rather than by a drop in cardiovascular deaths, so the fair reading is narrow: it helps this specific heart-failure population feel and do better, without proof that it prevents cardiovascular death broadly.

The broader safety question was tested in SURPASS-CVOT, which compared tirzepatide against dulaglutide, another GLP-1 drug that already has proven heart benefit. Tirzepatide was non-inferior for major cardiovascular events, meaning it held its own against a strong comparator, and it reduced all-cause death.⁵ What this trial did not do is compare tirzepatide against placebo, so it proves safety and rough equivalence rather than a standalone reduction in heart attacks and strokes.

That distinction is the key one. Semaglutide, in the placebo-controlled SELECT trial, cut major cardiovascular events by about 20% in people with heart disease and obesity but without diabetes. Tirzepatide has no equivalent placebo-controlled outcomes trial yet; the dedicated study, SURMOUNT-MMO, is still running. So the fair summary is that tirzepatide has demonstrated cardiovascular safety and a clear benefit in heart failure with obesity, while its broad heart-attack-and-stroke prevention remains to be proven the way semaglutide's has been.

Liver, sleep apnea, and the widening set of uses

Tirzepatide's reach is expanding as trials report. In SYNERGY-NASH, a phase 2 study in people with metabolic-associated steatohepatitis (MASH, the inflammatory form of fatty liver) and moderate-to-severe scarring, tirzepatide led to resolution of the liver disease in 44 to 62% of people across its doses, versus about 10% on placebo.⁶ That is a promising result, though it is an early-phase trial measuring liver biopsy changes rather than long-term outcomes, and tirzepatide is not approved for liver disease. Our fatty liver guide covers where this fits.

In December 2024, tirzepatide became the first medication approved for obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA, which showed a meaningful drop in the number of breathing interruptions per hour of sleep.⁷ For many people, the sleep-apnea and weight benefits reinforce each other.

Who is tirzepatide for, and what are the risks?

Tirzepatide suits adults with obesity, or with type 2 diabetes, who need substantial metabolic change and can tolerate an injectable. It is powerful, and that power calls for structure around it: a plan for protein and strength work to guard muscle, a realistic view of cost and access, and a clear-eyed sense that stopping the drug often brings some weight back unless habits have taken hold.

The side effects are mostly digestive: nausea, vomiting, diarrhea, and constipation, usually worst while the dose is being raised and better with slow escalation. The label carries a boxed warning for thyroid C-cell tumors, based on a signal seen in rodents; it has not been proven in people, but the drug should be avoided by anyone with a personal or family history of medullary thyroid cancer or the MEN2 syndrome. Less common risks include pancreatitis, gallbladder problems, dehydration from heavy vomiting or diarrhea that can strain the kidneys, and low blood sugar when combined with insulin or sulfonylureas. These are manageable with the right oversight, which is the case for using it within proper medical care rather than casually.

Guidance from the Clinic

"Tirzepatide is the most powerful metabolic drug we have, and I treat that power with respect rather than hype. For the right patient it can change the trajectory of obesity, diabetes, fatty liver, and even sleep apnea, and the head-to-head data putting it ahead of semaglutide are hard to ignore. What I hold the line on is muscle. Losing 20% of your body weight is only a win if most of it is fat, so protein and resistance training are non-negotiable parts of the plan rather than afterthoughts. I am also careful not to oversell the heart story. Tirzepatide is safe for the heart and helps a tough form of heart failure, but it has not yet proven it prevents heart attacks and strokes the way semaglutide has. I would rather tell you what we know and what we are still waiting on than let the marketing get ahead of the evidence."

Key Takeaways

Tirzepatide (Zepbound for weight, Mounjaro for diabetes) is a dual GIP and GLP-1 agonist, a step beyond semaglutide, which targets GLP-1 alone.
It produces the largest weight loss of any current medication, about 21% at the top dose in trials, and beat semaglutide head-to-head at full obesity doses, about 20% versus 14%.
Most of the weight lost is fat, but a meaningful share is muscle, so protein and resistance training belong in the plan from the start.
Its cardiovascular data show safety and a clear benefit in heart failure with obesity, but it has not yet matched semaglutide's placebo-controlled proof of preventing heart attacks and strokes.
It also improves fatty liver disease and is the first drug approved for obstructive sleep apnea in obesity; main risks are digestive, with a rodent-based boxed warning for thyroid tumors.

Ozempic vs Metformin - where each metabolic drug fits, semaglutide included
Muscle Loss on GLP-1 Drugs - protecting lean mass during rapid weight loss
Medical Weight Loss - building durable results around the medication
SGLT2 Inhibitors: Heart, Kidney, and Longevity - another organ-protective metabolic drug class
Retatrutide: The Triple Agonist - the investigational next step, adding a glucagon receptor
The New Weight-Loss Drugs, Compared - how tirzepatide stacks up against the whole field
Fatty Liver (MASLD) - where the liver benefit fits
Sleep Apnea: Wearables and Home Testing - tirzepatide is now approved for obesity-related sleep apnea
GLP-1 Drugs and Surgery - whether to hold or continue before a procedure
Compounded GLP-1 Drugs - are the compounded versions safe and legal now
GLP-1 Drugs and Heart Failure (HFpEF) - the SUMMIT heart-failure result in context

Scientific References

Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216.
Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." New England Journal of Medicine. 2025.
Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503-515.
Packer M, Zile MR, Kramer CM, et al. "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity." New England Journal of Medicine. 2025;392(5):427-437.
Nicholls SJ, Bhatt DL, Buse JB, et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes." New England Journal of Medicine. 2025;393:2409-2420.
Loomba R, Hartman ML, Lawitz EJ, et al. "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis." New England Journal of Medicine. 2024;391(4):299-310.
Malhotra A, Grunstein RR, Fietze I, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." New England Journal of Medicine. 2024.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Deep-Dive Questions

GLP-1 and GIP are both incretin hormones the gut releases after eating, and they act on partly different tissues and pathways. GLP-1 slows stomach emptying, curbs appetite, and improves insulin release; GIP adds effects on fat tissue and insulin handling and may blunt some of the nausea that limits GLP-1 doses. Engaging both receptors appears to produce a larger metabolic effect than either alone, which is the leading explanation for the greater weight loss seen in head-to-head studies. The full biology is still being worked out, and tirzepatide leans somewhat more on the GIP receptor, so calling it a perfectly balanced dual agonist would overstate what is known.

SUMMIT enrolled people who had both obesity and heart failure with a preserved ejection fraction, a form that stiffens the heart and has frustrated most drug trials. Tirzepatide reduced a combined endpoint of cardiovascular death or worsening heart failure and improved symptoms and walking capacity. The important detail is that the win came mostly from fewer heart-failure events rather than from fewer deaths, since the death numbers were small. So the grounded claim is that tirzepatide helps this specific group feel better and stay out of the hospital, which is meaningful, without stretching it into a general promise about preventing cardiovascular death.

Often not fully. Withdrawal studies of these drugs show that a meaningful portion of lost weight tends to return after stopping, because the medication is treating an ongoing biological drive rather than curing it. This is why we frame tirzepatide as a long-term tool for many people, and why the habits built while on it, strength training, protein, sleep, and food quality, matter so much for holding the result if and when the dose comes down.

Not in the way that word is often used. Its trials measure weight, blood sugar, heart failure, liver disease, and sleep apnea, rather than lifespan. That said, obesity and type 2 diabetes shorten life and drive many age-related diseases, so a drug that treats them well can plausibly support a longer, healthier life for the people who need it. The grounded framing is that tirzepatide is a powerful treatment for specific metabolic conditions, and improving those conditions is its own contribution to healthy aging, without needing an anti-aging label it has not earned.

Ready when you are